Sample Size Calculations in Thorough QT Studies

REFERENCES

• Beasley , C. M. , Mitchell , M. I. , Dmitrienko , A. A. , Emmick , J. T. , Shen , W. , Costigan , T. M. , Bedding , A. W. , Turik , M. A. , Bakhtyari , A. , Warner , M. R. , Ruskin , J. N. , Cantilena , L. R. , Kloner , R. A. ( 2005 ). The combined use of ibutilide as an active control with intensive ECG sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval . Journal of American College of Cardiology 46 : 678 – 687 .
   PubMed Web of Science ®Google Scholar
• Biopharmaceutical Network. List of published thorough QT studies. http://www.biopharmnet.com/doc/doc14001-01.html. Last accessed on April 10, 2008 .
   Google Scholar
• Boos , D. , Hoffman , D. , Kringle , R. , Zhang , J. (2007). New confidence bounds for QT studies. Statistics in Medicine 26:3801–3817.
   PubMed Web of Science ®Google Scholar
• Dmitrienko , A. , Smith , B. ( 2003 ). Repeated-measures models in the analysis of QT interval . Pharmaceutical Statistics 2 : 175 – 190 .
   Google Scholar
• Eaton , M. L. , Muirhead , R. J. , Mancuso , J. Y. , Lolluri , S. ( 2006 ). A confidence interval for the maximal mean QT interval change due drug effect . Drug Information Journal 40 : 267 – 271 .
   Google Scholar
• Extramiana , F. , Maison-Blanche , P. , Cabanis , M. J. , Ortemann-Renon , C. , Beaufils , P. , Leenhardt , A. ( 2005 ). Clinical assessment of drug-induced QT prolongation in association with heart rate changes . Clinical Pharmacology and Therapeutics 77 : 247 – 258 .
   PubMed Web of Science ®Google Scholar
• Fridericia , L. S. ( 1920 ). Die systolendauer im elecktrokardiogramm bei normalen menschen und bei herzkranken . Acta Medica Scandinavia 53 : 469 – 486 .
   Google Scholar
• Genz , A. , Bretz , F. ( 2002 ). Methods for the computation of multivariate t-probabilities . Journal of Computational and Graphical Statistics 11 : 950 – 971 .
   Web of Science ®Google Scholar
• ICH E14 . ( 2005 ). Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs .
   Google Scholar
• Ma , H. , Smith , B. , Dmitrienko , A. ( 2008 ). Statistical analysis methods for QT/QTc prolongation . Journal of Biopharmaceutical Statistics (In press) .
   Google Scholar
• Malhotra , B. K. , Glue1 , P. , Sweeney , K. , Anziano , R. , Mancuso , J. , Wicker , P. ( 2007 ). Thorough QT study with recommended and supratherapeutic doses of tolterodine . Clinical Pharmacology and Therapeutics 81 : 377 – 385 .
   PubMed Web of Science ®Google Scholar
• Patterson , S. , Jones , B. , Zariffa , N. ( 2005 ). Modeling and interpreting QTc prolongation in clinical pharmacology studies . Drug Information Journal 39 : 437 – 445 .
   Web of Science ®Google Scholar
• Serra , D. B. , Affrime , M. B. , Bedigian , M. P. , Greig , G. , Milosavljev , S. , Skerjanec , A. , Wang , Y. ( 2005 ). QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder . Journal of Clinical Pharmacology 45 : 1038 – 1047 .
   PubMed Web of Science ®Google Scholar
• Zhang , J. ( 2007 ). Current E14-derived approach to design and statistical analysis of TQT studies . Presentation at the 2007 American College of Clinical Pharmacy Symposium, Baltimore .
   Google Scholar
• Zhang , L. , Chappell , J. , Gonzales , C. , Small , D. , Knadler , M. , Callaghan , J. T. , Francis , J. L. , Desaiah , D. , Leibowitz , M. , Ereshefsky , L. , Hoelscher , D. , Leese , P. T. , Derby , M. ( 2007 ). QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study . Journal of Cardiovascular Pharmacology 49 : 146 – 153 .
   PubMed Web of Science ®Google Scholar
• Zhang , L. , Smith , B. ( 2007 ). Sex differences in QT interval variability and implication on sample size of thorough QT studies . Drug Information Journal 5 : 619 – 627 .
   Google Scholar